首页> 美国卫生研究院文献>Systems and Synthetic Biology >Design of a novel nucleoside analog as potent inhibitor of the NAD+ dependent deacetylase SIRT2
【2h】

Design of a novel nucleoside analog as potent inhibitor of the NAD+ dependent deacetylase SIRT2

机译:一种新型核苷类似物作为NAD +依赖性脱乙酰基酶SIRT2的有效抑制剂的设计

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Sirtuins (class III histone deacetylase) are evolutionarily conserved NAD+-dependent enzymes that catalyze the deacetylation of acetyl-lysine residues of histones and other target proteins. Because of their associations in various pathophysiological conditions, the identification of small molecule modulators has been of significant interest. In the present study, virtual screening was carried out with NCI Diversity Set II using crystal structure of hSIRT2 (PDB ID: 1J8F) as a model for the docking procedure to find potential compounds, which were then subjected to experimental tests for their in vitro SIRT2 inhibitory activity. One of the 40 compounds tested, NSC671136 (IUPAC name: 6-Acetyl-4-oxo-1,3-diphenyl-2-thioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-5-yl 2,4-dichlorobenzoate) has structurally unique scaffold, showed strong inhibitory activity towards SIRT2 with IC50 of ~8.7 μM and to a lesser extent on SIRT1 activity. The reported compound is substantially potent compared to the published SIRT2 inhibitors and serves as an excellent base for future lead development.
机译:Sirtuins(III类组蛋白去乙酰化酶)是进化上保守的NAD + 依赖性酶,可催化组蛋白和其他靶蛋白的乙酰赖氨酸残基脱乙酰化。由于它们在各种病理生理条件下的关联,对小分子调节剂的鉴定已引起了极大的兴趣。在本研究中,使用hSIRT2(PDB ID:1J8F)的晶体结构作为对接程序的模型,使用NCI多样性组II进行了虚拟筛选,以寻找潜在的化合物,然后对其体外SIRT2进行实验测试抑制活性。 NSC671136(IUPAC名称:6-乙酰基-4-氧代-1,3-二苯基-2-硫代氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-5- 2,4-二氯苯甲酸基酯)具有独特的结构支架,对SIRT2具有很强的抑制活性,IC50为8.7μM,对SIRT1的活性较小。与已发表的SIRT2抑制剂相比,所报道的化合物具有显着的效力,并且是未来铅开发的优良基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号